IL22 and myeloid sarcoma: High levels of IL-22 and of IL-22 producing cells have been detected in the serum, CSF, and peripheral blood of MS patients [140–142], and it has been demonstrated that IL-22 promotes the disruption of BBB in vitro and in vivo [126].